FKFernanda Christtanini Koyama

Fernanda Christtanini Koyama

*This is an algorithmically generated author record based on publicly available information.

Fernanda Christtanini Koyama has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Genomic profiling by circulating tumor DNA in patients with hormone receptor-positive/HER2-negative advanced breast cancer: Prevalence of actionable mutations across treatment lines

    by Rodrigo Dienstmann, Márcio Luiz Martins Júnior, Breno Jeha Araújo, Cristiano Augusto Andrade de Resende, Rafael Duarte Paes, Christopher Lucas Negrete, Leandro Moreno Silveira da Silva, Daniela Jessica Pereira, Gustavo de Oliveira Bretas, Larissa Muller Gomes, et al.

  • Open Access

    Timely Broad Genomic Profiling Improves Delivery of Matched Therapy in Advanced NSCLC: A Nationwide Real-World Study from Brazil

    by Breno Jeha Araujo, Rafael Paes, Christopher Lucas Negrete, Nathalia Pellegrini Correa, Fernanda Koyama, Jéssica Vieira de Assis, Carolina de Bustamante Fernandes, Clarissa Mathias, Mariana Tosello Laloni, Ana Caroline Zimmer Gelatti, et al.

    Background: Broad next-generation sequencing (NGS) is essential to identify actionable genomic alterations (AGA) in advanced non-squamous non-small-cell lung cancer (nsNSCLC), but its clinical benefit depends on timely molecular results to guide first-line treatment. We evaluated the impact of NGS timing on treatment selection and clinical outcomes.Methods: We retrospectively evaluated patients with advanced nsNSCLC who underwent centralized molecular profiling through a nationwide patient support program (Brazil, June 2020-December 2023). Treatment lines were defined according to the ESMO EnLiST framework. The primary endpoint was the proportion of patients with AGA receiving genotype-matched therapy in the first-line setting. Secondary endpoints included diagnostic intervals, time to treatment discontinuation (TTD), overall survival (OS), and treatment allocation by NGS timing.Results: Among 1,510 submitted samples, 1,056 (70%) yielded informative NGS results. Of 318 outcome-evaluable patients, 101 (32%) harbored AGA, of whom 89 (88.1%; 95% CI, 80.4–93.1%) received matched therapy in the first-line setting. Overall, 73% of patients initiated first-line treatment after NGS results became available, which was associated with a higher likelihood of matched therapy (OR 5.86; P<0.001) and longer TTD (6.3 vs 2.6 months; HR 0.59; P<0.001). Among patients with AGA, matched therapy was associated with significantly longer TTD (21.2 vs 3.5 months; HR 0.25; P < 0.001) and OS (45.4 vs 16.3 months; HR 0.44; P = 0.019) than non-targeted systemic therapy.Conclusion: Within a nationwide precision oncology program, matched therapy was delivered to nearly 90% of patients with AGA. Earlier NGS result availability improved delivery of precision oncology, whereas receipt of matched therapy was associated with improved overall survival.

  • Clinical Response to Poly(ADP-ribose) Polymerase Inhibitor in Metastatic Breast Cancer With a Germline Reduced-Penetrance BRCA2 Pathogenic Variant: A Molecular Tumor Board Discussion

    by Diocésio Alves Pinto de Andrade, Carlos Alberto Fruet Filho, Cristiane Alves Mendes, Eduardo Miguel Febrônio, Viviane Fernandes Schiavon, Carolina de Bustamante Fernandes, Fernanda Christtanini Koyama, Patrícia Ashton-Prolla, Rodrigo Dienstmann, Leandro Jonata de Carvalho Oliveira

  • Increased detection of NRG1 fusions in non-squamous non–small cell lung cancer using combined DNA and RNA sequencing in a real-world cohort

    by Breno Jeha Araújo, Filipe Visani, Rafael Duarte Paes, Christopher Lucas Negrete, Nathalia Pellegrini Correa, Fernanda Christtanini Koyama, Jéssica Vieira de Assis, Luciana Guedes de Almeida Valverde, Carolina de Bustamante Fernandes, Clarissa Mathias, et al.


  • Open Access

    Effect of Akt activation and experimental pharmacological inhibition on responses to neoadjuvant chemoradiotherapy in rectal cancer

    by F C Koyama, C M Lopes Ramos, F Ledesma, V A F Alves, J M Fernandes, B B Vailati, G P São Julião, A Habr-Gama, J Gama-Rodrigues, R O Perez, et al.

    Background: Neoadjuvant chemoradiotherapy (CRT) is one of the preferred initial treatment strategies for locally advanced rectal cancer. Responses are variable, and most patients still require surgery. The aim of this study was to identify molecular mechanisms determining poor response to CRT. Methods: Global gene expression and pathway enrichment were assessed in pretreatment biopsies from patients with non-metastatic cT2–4 N0–2 rectal cancer within 7 cm of the anal verge. Downstream Akt activation was assessed in an independent set of pretreatment biopsies and in colorectal cancer cell lines using immunohistochemistry and western blot respectively. The radiosensitizing effects of the Akt inhibitor MK2206 were assessed using clonogenic assays and xenografts in immunodeficient mice. Results: A total of 350 differentially expressed genes were identified, of which 123 were upregulated and 199 downregulated in tumours from poor responders. Mitochondrial oxidative phosphorylation (P < 0·001) and phosphatidylinositol signalling pathways (P < 0·050) were identified as significantly enriched pathways among the set of differentially expressed genes. Deregulation of both pathways is known to result in Akt activation, and high immunoexpression of phosphorylated Akt S473 was observed among patients with a poor histological response (tumour regression grade 0–2) to CRT (75 per cent versus 48 per cent in those with a good or complete response; P = 0·016). Akt activation was also confirmed in the radioresistant cell line SW480, and a 50 per cent improvement in sensitivity to CRT was observed in vitro and in vivo when SW480 cells were exposed to the Akt inhibitor MK2206 in combination with radiation and 5-fluorouracil. Conclusion: Akt activation is a key event in the response to CRT. Pharmacological inhibition of Akt activation may enhance the effects of CRT. Surgical relevanceOrgan preservation is an attractive alternative in rectal cancer management following neoadjuvant chemoradiotherapy (CRT) to avoid the morbidity of radical surgery. Molecular steps associated with tumour response to CRT may provide a useful tool for the identification of patients who are candidates for no immediate surgery.In this study, tumours resistant to CRT were more likely to have activation of specific genetic pathways that result in phosphorylated Akt (pAkt) activation. Pretreatment biopsy tissues with high immunoexpression of pAkt were more likely to exhibit a poor histological response to CRT. In addition, the introduction of a pAkt inhibitor to cancer cell lines in vitro and in vivo led to a significant improvement in sensitivity to CRT.Identification of pAkt-activated tumours may thus allow the identification of poor responders to CRT. In addition, the concomitant use of pAkt inhibitors to increase sensitivity to CRT in patients with rectal cancer may constitute an interesting strategy for increasing the chance of a complete response to treatment and organ preservation.


  • Damaging germline variants in TSC2 are frequently found among nonsyndromic patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NETs)

    by R.D.M. Linck, P.F. Asprino, F.P. Freitas, F.C. Koyama, P.A.F. Galante, R. Riechelmann, L.F.L. Reis, F.P. Costa, P.M. Hoff, A.A. Camargo, et al.

  • Open Access

    Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients

    by Camila Miranda Lopes-Ramos, Angelita Habr-Gama, Bruna de Souza Quevedo, Natália Mariana Felício, Fabiana Bettoni, Fernanda Christtanini Koyama, Paula Fontes Asprino, Pedro Alexandre Galante, Joaquim Gama-Rodrigues, Anamaria Aranha Camargo, et al.

    Neoadjuvant chemoradiotherapy (nCRT) followed by radical surgery is the preferred treatment strategy for locally advanced rectal cancer. However, complete tumor regression is observed in a significant proportion of patients after nCRT, making them ideal candidates for alternative treatment strategies to this considerably morbid procedure. Identification of such patients based on clinical findings (complete clinical response - cCR) is difficult mainly because it relies on subjective clinical and imaging studies. Our goal was to identify biomarkers capable of predicting complete response to nCRT. We analyzed miRNA expression profile using deep sequencing in rectal tumor biopsies prior to nCRT. Differential expression was investigated by EdgeR for a training (n = 27) and a validation (n = 16) set of patients to identify miRNAs associated with treatment response (complete vs. incomplete). In vitro experiments with two cancer cell lines were also performed in order to evaluate the possible role of miRNAs on response to nCRT. We found 4 miRNAs differentially expressed between complete and incomplete responders to nCRT. In addition, validation was performed using an independent group of patients and miR-21-5p was confirmed as being overexpressed in complete responders. Overall sensitivity and specificity of miR-21-5p expression in predicting complete response to nCRT was 78% and 86% respectively. Interestingly, in a subset of patients with cCR followed by early local recurrence, the expression level of miR-21-5p was considerably low, similarly to incomplete responders. We also found SATB1, a miR-21-5p target gene and known multidrug resistance gene, whose expression was inversely correlated with miR-21-5p expression. Finally, we performed functional experiments and showed that miR-21-5p and SATB1 may be directly involved with poor response to nCRT in rectal cancer patients. This study suggests miR-21-5p as a promising predictive biomarker, which should aid in the selection of patients with cCR to nCRT that potentially could be spared from radical surgery.